Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Chronic Kidney Disease IV: Nursing Management

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Nephrotic Syndrome III : Nursing Management

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Response to the Letter to the Editor Entitled "A Missing Genomic Dimension: The Small but Central Mitochondrial Genome in Diabetic Kidney Disease Genetics".

Kidney international reports·2026

Same author

Using a generative co-design framework to adapt an exercise intervention as part of a multimodal intervention for patients' receiving haemodialysis with or at risk of renal cachexia.

Research involvement and engagement·2026

Same author

Exploring Telomere Association in Donor-Recipient Pairs: Implications for Kidney Graft Longevity.

Life (Basel, Switzerland)·2026

Same author

Multi-modal integrated intervention combining exercise, anti-inflammatory, and dietary advice (MMIEAD) for adults with kidney cachexia: protocol for a mixed-methods feasibility cluster randomised controlled trial and process evaluation.

Pilot and feasibility studies·2026

Same author

Anti-inflammatory effects and safety of omega-3 fatty acids in haemodialysis: A systematic review and meta-analysis.

Clinical nutrition ESPEN·2026

Same author

Blood DNA methylation markers are associated with diabetic kidney disease progression in type 1 diabetes.

Diabetologia·2026

Same journal

Finerenone Exposure and Ischemic Stroke in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity Score-Matched Cohort Study.

Clinical medicine (London, England)·2026

Same journal

Prevalence and predictive factors of chronic kidney disease among individuals with cardiometabolic risk factors: A multicenter cross sectional study, North East Ethiopia.

Clinical medicine (London, England)·2026

Same journal

Authors' response to Dr Lucy Williams' letter to the Editor: 'Life expectancy of UK physicians in the early 21st century: An analysis of 1,000 fellows from the Royal College of Physicians' Munk's Roll'.

Clinical medicine (London, England)·2026

Same journal

Resident doctor workforce wellbeing worldwide: lessons between the United Kingdom and Australia.

Clinical medicine (London, England)·2026

Same journal

Premature ventricular complexes.

Clinical medicine (London, England)·2026

Same journal

Heart failure with preserved ejection fraction (HFpEF): diagnosis and management for the general physician.

Clinical medicine (London, England)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Managing diabetic nephropathy.

Joanne Shields¹, Alexander P Maxwell

¹Regional Nephrology Unit, Belfast City Hospital.

Clinical Medicine (London, England)

|December 2, 2010

Summary

This summary is machine-generated.

Diabetic nephropathy (DN) begins with microalbuminuria, increasing risks for kidney failure and heart disease. Managing blood sugar and pressure, using RAAS blockers, can prevent, slow, or reverse DN.

Related Experiment Videos

Last Updated: Jun 6, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Area of Science:

Nephrology
Cardiology
Endocrinology

Background:

Diabetic nephropathy (DN) is a significant complication of diabetes.
Microalbuminuria is the earliest clinical marker of DN.
DN increases the risk of end-stage renal disease and cardiovascular mortality.

Purpose of the Study:

To highlight the clinical significance of microalbuminuria in DN.
To emphasize the importance of glycemic and blood pressure control in managing DN.
To discuss the role of RAAS blocking drugs in DN treatment.

Main Methods:

Review of current literature on diabetic nephropathy.
Analysis of risk factors associated with microalbuminuria.
Evaluation of therapeutic strategies for DN.

Main Results:

Microalbuminuria predicts progressive renal failure and cardiovascular events.
Optimal glycemic control is crucial for preventing DN progression.
Blood pressure management, including RAAS blockade, effectively mitigates DN.

Conclusions:

Early detection and management of microalbuminuria are vital in diabetic patients.
Comprehensive management of hyperglycemia and hypertension is essential for renal and cardiovascular protection.
RAAS inhibitors are key therapeutic agents in slowing or reversing DN.